Harrow shares rise 10.38% intraday as CVS elevates Vevye to Tier 1 formulary, boosting patient access and growth prospects.

Harrow (HROW) surged 10.38% intraday after CVS Health elevated its dry eye drug Vevye to Tier 1 coverage on its pharmacy benefit manager formulary, a move expected to enhance patient access and prescription volumes. This formulary upgrade, coupled with recent investor presentations at key healthcare conferences, reinforced Harrow’s growth narrative in branded ophthalmic pharmaceuticals. Other news, including local Harrow events and unrelated UK diplomatic reviews, held no material relevance to the stock’s performance.